A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein

作者：Massignan Tania; Cimini Sara; Stincardini Claudia; Cerovic Milica; Vanni Ilaria; Elezgarai Saioa R; Moreno Jorge; Stravalaci Matteo; Negro Alessandro; Sangiovanni Valeria; Restelli Elena; Riccardi Geraldina; Gobbi Marco; Castilla Joaquin; Borsello Tiziana; Nonno Romolo; Biasini Emiliano^*

来源：Scientific Reports, 2016, 6(1): 23180.

DOI：10.1038/srep23180

Prion diseases are rare neurodegenerative conditions associated with the conformational conversion of the cellular prion protein (PrPC) into PrPSc, a self-replicating isoform (prion) that accumulates in the central nervous system of affected individuals. The structure of PrPSc is poorly defined, and likely to be heterogeneous, as suggested by the existence of different prion strains. The latter represents a relevant problem for therapy in prion diseases, as some potent anti-prion compounds have shown strain-specificity. Designing therapeutics that target PrPC may provide an opportunity to overcome these problems. PrPC ligands may theoretically inhibit the replication of multiple prion strains, by acting on the common substrate of any prion replication reaction. Here, we characterized the properties of a cationic tetrapyrrole [Fe(III)-TMPyP], which was previously shown to bind PrPC, and inhibit the replication of a mouse prion strain. We report that the compound is active against multiple prion strains in vitro and in cells. Interestingly, we also find that Fe(III)-TMPyP inhibits several PrPC-related toxic activities, including the channel-forming ability of a PrP mutant, and the PrPC-dependent synaptotoxicity of amyloid-beta (A beta) oligomers, which are associated with Alzheimer's Disease. These results demonstrate that molecules binding to PrPC may produce a dual effect of blocking prion replication and inhibiting PrPC-mediated toxicity.

• 出版日期2016-3-15